Patents by Inventor Catherine A. Brennan

Catherine A. Brennan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolotriazine Derivatives Useful For Treating Hyper-Proliferative Disorders And Diseases Associated With Angiogenesis
    Publication number: 20070208013
    Abstract: This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.
    Type: Application
    Filed: June 3, 2005
    Publication date: September 6, 2007
    Applicant: BAYER PHARMACEUTICALS CORPORATION
    Inventors: Julie Dixon, Catherine Brennan, Karl Miranda, Brent Chandler, Barton Phillips, Jianmei Fan, Michael Brands, Andrea Mcclure, Benjamin Jones, Wenlang Fu, Donald Bierer, Steven Magnuson, Harold Kluender
  • Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
    Patent number: 7238701
    Abstract: The present invention relates to a compound of Formula (I) and its use in treating lung and breast cancer.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: July 3, 2007
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Chengzhi Zhang, Gaetan H. Ladouceur, Catherine Brennan, Brent Chandler, Julie A. Dixon, Karl Miranda, Dongping Fan, Qingming Zhu, Sharad Verma, Jacques Dumas
  • Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
    Publication number: 20060293322
    Abstract: The present invention relates to a compound of Formula (I) and its use in treating hyper-proliferative disorders.
    Type: Application
    Filed: July 23, 2004
    Publication date: December 28, 2006
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Chengzhi Zhang, Gaetan Ladouceur, Catherine Brennan, Brent Chandler, Julie Dizon, Karl Miranda, Dongping Fan, Qingming Zhu, Sharad Verma, Jacques Dumas
  • Novel antigen constructs useful in the detection and differentiation of antibodies to HIV
    Publication number: 20060153866
    Abstract: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.
    Type: Application
    Filed: December 9, 2004
    Publication date: July 13, 2006
    Inventors: John Hackett, Julie Yamaguchi, Alan Golden, Catherine Brennan, Robert Hickman, Sushil Devare
  • Antigen constructs useful in the detection and differentiation of antibodies to HIV
    Patent number: 6846905
    Abstract: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.
    Type: Grant
    Filed: August 15, 1997
    Date of Patent: January 25, 2005
    Assignee: Abbott Laboratories
    Inventors: John R. Hackett, Jr., Julie Yamaguchi, Alan M. Golden, Catherine A. Brennan, Robert K. Hickman, Sushil G. Devare
  • Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
    Publication number: 20040102636
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: February 1, 2002
    Publication date: May 27, 2004
    Applicant: BAYER CORPORATION
    Inventors: Scott Miller, Martin Osterhout, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, David E. Gunn, Holia Hatoum-Mokdad, Marell Rodriguez, Robert Sibley, Ming Wang, Tiffany Turner, Catherine Brennan
  • NOVEL ANTIGEN CONSTRUCTS USEFUL IN THE DETECTION AND DIFFERENTION OF ANTIBODIES TO HIV
    Publication number: 20030004323
    Abstract: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp4l IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.
    Type: Application
    Filed: August 15, 1997
    Publication date: January 2, 2003
    Inventors: JOHN R. HACKETT, JR., JULIE YAMAGUCHI, ALAN M. GOLDEN, CATHERINE A. BRENNAN, ROBERT K. HICKMAN, SUSHIL G. DEVARE
  • Rapid assay for simultaneous detection and differentiation of antibodies to HIV groups
    Patent number: 5922533
    Abstract: A method of performing a rapid assay for the simultaneous detection and differentiation of the analytes HIV-1 group M. HIV-1 group O and HIV-2 utilizing a sequence specific polypeptide of each analyte as capture reagents. An analytical. device also is provided for performing the method which includes these capture reagents. Also provided is a test kit which includes the analytical device which further can include a positive and negative control.
    Type: Grant
    Filed: August 15, 1997
    Date of Patent: July 13, 1999
    Assignee: Abbott Laboratories
    Inventors: Anadruzela S. Vallari, John R. Hackett, Jr., Robert K. Hickman, Vincent A. Varitek, Jr., Elizabeth C. Necklaws, Alan M. Golden, Catherine A. Brennan, Sushil G. Devare
  • Genetically engineered enzymes and their conjugates for diagnostic assays
    Patent number: 5843634
    Abstract: This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate.
    Type: Grant
    Filed: June 4, 1996
    Date of Patent: December 1, 1998
    Assignee: Abbott Laboratories
    Inventors: Elaine M Brate, Catherine A. Brennan, Dominique P. Bridon, Keeve D. Jaffe, Grant A. Krafft, Wlodzimierz Mandecki, Steven C. March, John C. Russell, Vincent T. Yue